{"id":"W4390904689","doi":"10.25251/skin.8.supp.349","title":"Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Genentech; LEO Pharma; Sanofi Genzyme; Incyte; National Eczema Association; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Biogen; Amgen; Pfizer; Galderma; Eli Lilly and Company; Sanofi","keywords":"Hidradenitis suppurativa; Medicine; Double blind; Placebo; Multicenter study; Pooled analysis; Internal medicine; Multicenter trial; Dermatology; Randomized controlled trial; Pathology; Alternative medicine; Meta-analysis; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00966309,0.001350257,0.005411576,0.0008913357,0.0004591575,0.001855752,0.0007323341,0.001794176,0.002965081],"category_scores_gemma":[0.009349682,0.0007022976,0.00821548,0.00101057,0.0007436628,0.001405718,0.0006377955,0.001997633,0.00032029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005414601,"about_ca_system_score_gemma":0.0007543517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005894939,"about_ca_topic_score_gemma":0.001668768,"domain_scores_codex":[0.9947885,0.003042694,0.0008073843,0.0005380945,0.0005650374,0.000258286],"domain_scores_gemma":[0.9935758,0.00298113,0.002061116,0.000481902,0.0003928656,0.0005071691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8762293,0.00172668,0.01000633,0.01027555,0.05605849,0.00007056024,0.0001039045,0.0007423008,0.002649869,0.0001420596,0.001648774,0.04034614],"study_design_scores_gemma":[0.7693917,0.08361153,0.06612289,0.001518651,0.07015625,0.0003203812,0.0001131941,0.001068361,0.00147787,0.0005215025,0.005577187,0.0001204764],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6789225,0.2999586,0.002388292,0.001142588,0.001040748,0.005114361,0.005725748,0.0002226799,0.005484577],"genre_scores_gemma":[0.9636315,0.02733359,0.001464984,0.001089989,0.0007931224,0.002305923,0.002579698,0.00002989786,0.0007713095],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00966309,"threshold_uncertainty_score":0.05110389,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05229412364784481,"score_gpt":0.3412784765418269,"score_spread":0.2889843528939821,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}